The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
Open accessAbstract
BACKGROUND & AIMS: Sorafenib, an oral multikinase inhibitor, significantly prolonged overall survival (OS) vs. placebo in patients with unresectable hepatocellular carcinoma (HCC) in two phase III studies, SHARP (Sorafenib HCC Assessment Randomized Protocol) and Asia Pacific (AP). To assess prognostic factors for HCC and predictive factors of sorafenib benefit, we conducted a pooled exploratory analysis from these placebo-controlled phase III studies. METHODS: To identify potential prognostic factors for OS, univariate and multivariate (MV) analyses were performed for baseline variables by Cox proportional hazards model. Hazard ratios (HRs) and median OS were evaluated across pooled subgroups. To assess factors predictive of sorafenib benefit, the interaction term between treatment for each subgroup was evaluated by Cox proportional hazard model. RESULTS: In 827 patients (448 sorafenib; 379 placebo) analyzed, strong prognostic factors for poorer OS identified from MV analysis in both treatment arms were presence of macroscopic vascular invasion (MVI), high alpha-fetoprotein (AFP), and high neutrophil-to-lymphocyte ratio (NLR; ⩽ vs. >median [3.1]). Sorafenib OS benefit was consistently observed across all subgroups. Significantly greater OS sorafenib benefit vs. placebo was observed in patients without extrahepatic spread (EHS; HR, 0.55 vs. 0.84), with hepatitis C virus (HCV) (HR, 0.47 vs. 0.81), and a low NLR (HR, 0.59 vs. 0.84). CONCLUSIONS: In this exploratory analysis, presence of MVI, high AFP, and high NLR were prognostic factors of poorer OS. Sorafenib benefit was consistently observed irrespective of prognostic factors. Lack of EHS, HCV, and lower NLR were predictive of a greater OS benefit with sorafenib. LAY SUMMARY: This exploratory pooled analysis showed that treatment with sorafenib provides a survival benefit in all subgroups of patients with HCC; however, the magnitude of benefit is greater in patients with disease confined to the liver (without extrahepatic spread), or in those with hepatitis C virus, or a lower neutrophil-to-lymphocyte ratio, an indicator of inflammation status. These results help inform the prognosis of patients receiving sorafenib therapy and provide further refinements for the design of trials testing new agents vs. sorafenib. Clinical Trial Numbers: NCT00105443 and NCT00492752.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationImmunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Self-citationTempleton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F. E., Aneja, P., Ocaña, A., Leibowitz-Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 2,829
Johnson, P. J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H. L., O'Beirne, J., Fox, R., Skowronska, A., Palmer, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9151 · Cited by 2,783
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Bruix, J., Reig, M., & Sherman, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.041 · Cited by 1,694
Self-citationThe systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
Guthrie, G. J. K., Charles, K. A., Roxburgh, C. S. D., Horgan, P. G., McMillan, D. C., & Clarke, S. J. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.03.010 · Cited by 1,552
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Self-citationBruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822
Self-citationAggarwal, B. B., Vijayalekshmi, R. V., & Sung, B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0149 · Cited by 795
Yau, T., Tang, V. Y. F., Yao, T.-J., Fan, S.-T., Lo, C.-M., & Poon, R. T. P. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.032 · Cited by 698
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.103 · Cited by 621
Self-citationKudo, M., Matsui, O., Izumi, N., Iijima, H., Kadoya, M., Imai, Y., Okusaka, T., Miyayama, S., Tsuchiya, K., Ueshima, K., et al. (2014) · Liver Cancer · doi:10.1159/000343875 · Cited by 615
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Llovet, J. M., Peña, C. E. A., Lathia, C. D., Shan, M., Meinhardt, G., & Bruix, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2175 · Cited by 559
Self-citationTreatment of intermediate-stage hepatocellular carcinoma
Forner, A., Gilabert, M., Bruix, J., & Raoul, J.-L. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.122 · Cited by 466
Self-citationVerslype, C., Rosmorduc, O., & Rougier, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds225 · Cited by 365
Sieghart, W., Hucke, F., Pinter, M., Graziadei, I., Vogel, W., Müller, C., Heinzl, H., Trauner, M., & Peck-Radosavljevic, M. (2013) · Hepatology · doi:10.1002/hep.26256 · Cited by 343
Cheng, A.-L., Guan, Z., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Yang, T.-S., Tak, W. Y., Pan, H., Yu, S., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.006 · Cited by 259
Self-citationThe Role of Inflammation in the Pathogenesis of Non-small Cell Lung Cancer
O'Callaghan, D. S., O'Donnell, D., O'Connell, F., & O'Byrne, K. J. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f387e4 · Cited by 241
Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis
Xiao, W.-K., Chen, D., Li, S.-Q., Fu, S.-J., Peng, B.-G., & Liang, L.-J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-117 · Cited by 231
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Reig, M., Torres, F., Rodriguez-Lope, C., Forner, A., LLarch, N., Rimola, J., Darnell, A., Ríos, J., Ayuso, C., & Bruix, J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.030 · Cited by 228
Self-citationWang, J., Jia, Y., Wang, N., Zhang, X., Tan, B., Zhang, G., & Cheng, Y. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-7 · Cited by 166
Jackson, R., Psarelli, E., Berhane, S., Khan, H., & Johnson, P. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.5197 · Cited by 153
The Primary Outcome Is Positive — Is That Good Enough?
Pocock, S., & Stone, G. W. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1601511 · Cited by 146
Xue, T., Zhang, L., Xie, X.-Y., Ge, N., Li, L.-X., Zhang, B., Ye, S., & Ren, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096072 · Cited by 133
Raoul, J., Bruix, J., Greten, T. F., Sherman, M., Mazzaferro, V., Hilgard, P. A., Scherübl, H., Scheulen, M. E., Germanidis, G. S., Dominguez, S., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.009 · Cited by 131
Self-citationQi, X., Li, J., Deng, H., Li, H., Su, C., & Guo, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9942 · Cited by 112
Gardini, A. C., Scarpi, E., Faloppi, L., Scartozzi, M., Silvestris, N., Santini, D., de Stefano, G., Marisi, G., Negri, F., Foschi, F. G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11565 · Cited by 99
Ogasawara, S., Chiba, T., Ooka, Y., Kanogawa, N., Saito, T., Motoyama, T., Suzuki, E., Tawada, A., Kanai, F., & Yokosuka, O. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0237-3 · Cited by 98
Cho, J., Paik, Y., Lim, H. Y., Kim, Y. G., Lim, H. K., Min, Y. W., Gwak, G., Choi, M. S., Lee, J. H., Koh, K. C., et al. (2013) · Liver International · doi:10.1111/liv.12168 · Cited by 82
Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib
Ozenne, V., Paradis, V., Pernot, S., Castelnau, C., Vullierme, M., Bouattour, M., Valla, D. C., Farges, O., & Degos, F. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283386053 · Cited by 72
Hong Kong Consensus Recommendations on the Management of Hepatocellular Carcinoma
Poon, R. T. P., Cheung, T. T.-T., Kwok, P. C., Lee, A., Li, T.-W., Loke, K.-L., Chan, S. L., Cheung, M., Lai, T.-W., Cheung, C., et al. (2015) · Liver Cancer · doi:10.1159/000367728 · Cited by 46
Sun, X.-D., Shi, X., Chen, Y., Wang, C.-L., Ma, Q., & Lv, G. (2015) · Gastroenterology Research and Practice · doi:10.1155/2016/4743808 · Cited by 42
Prognostic and treatment-predictive factors—is there a difference?
Adolfsson, J., & Steineck, G. (2000) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500490 · Cited by 21
de Souza, A. R., Reig, M., & Bruix, J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1225722 · Cited by 17
Self-citation
Cited by
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationForner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Self-citationVogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Molecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
Self-citationEpidemiology and Management of Hepatocellular Carcinoma
Kulik, L., & El-Serag, H. B. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.08.065 · Cited by 1,735
Metadata
- Authors
- Bruix, J., Cheng, A.-L., Meinhardt, G., Nakajima, K., De Sanctis, Y., & Llovet, J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 67
- Issue
- 5
- Pages
- 999-1008
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2727497670
- Cited by
- 562
- References
- 40
- FWCI
- 33.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.